S&P 500   4,447.27 (-0.04%)
DOW   34,758.45 (-0.02%)
QQQ   371.53 (-0.39%)
AAPL   146.18 (-0.44%)
MSFT   298.02 (-0.51%)
FB   347.42 (+0.42%)
GOOGL   2,831.07 (+0.24%)
TSLA   764.28 (+1.41%)
AMZN   3,400.16 (-0.46%)
NVDA   219.24 (-2.48%)
BABA   145.80 (-3.57%)
NIO   35.51 (-1.39%)
CGC   13.99 (-3.91%)
GE   104.08 (+1.09%)
MU   74.38 (+0.46%)
AMD   105.00 (-1.08%)
T   27.29 (+0.37%)
F   13.93 (+1.60%)
ACB   6.01 (-2.28%)
DIS   175.56 (-0.39%)
PFE   44.18 (-0.02%)
BA   221.87 (+0.35%)
BAC   42.11 (+1.01%)
S&P 500   4,447.27 (-0.04%)
DOW   34,758.45 (-0.02%)
QQQ   371.53 (-0.39%)
AAPL   146.18 (-0.44%)
MSFT   298.02 (-0.51%)
FB   347.42 (+0.42%)
GOOGL   2,831.07 (+0.24%)
TSLA   764.28 (+1.41%)
AMZN   3,400.16 (-0.46%)
NVDA   219.24 (-2.48%)
BABA   145.80 (-3.57%)
NIO   35.51 (-1.39%)
CGC   13.99 (-3.91%)
GE   104.08 (+1.09%)
MU   74.38 (+0.46%)
AMD   105.00 (-1.08%)
T   27.29 (+0.37%)
F   13.93 (+1.60%)
ACB   6.01 (-2.28%)
DIS   175.56 (-0.39%)
PFE   44.18 (-0.02%)
BA   221.87 (+0.35%)
BAC   42.11 (+1.01%)
S&P 500   4,447.27 (-0.04%)
DOW   34,758.45 (-0.02%)
QQQ   371.53 (-0.39%)
AAPL   146.18 (-0.44%)
MSFT   298.02 (-0.51%)
FB   347.42 (+0.42%)
GOOGL   2,831.07 (+0.24%)
TSLA   764.28 (+1.41%)
AMZN   3,400.16 (-0.46%)
NVDA   219.24 (-2.48%)
BABA   145.80 (-3.57%)
NIO   35.51 (-1.39%)
CGC   13.99 (-3.91%)
GE   104.08 (+1.09%)
MU   74.38 (+0.46%)
AMD   105.00 (-1.08%)
T   27.29 (+0.37%)
F   13.93 (+1.60%)
ACB   6.01 (-2.28%)
DIS   175.56 (-0.39%)
PFE   44.18 (-0.02%)
BA   221.87 (+0.35%)
BAC   42.11 (+1.01%)
S&P 500   4,447.27 (-0.04%)
DOW   34,758.45 (-0.02%)
QQQ   371.53 (-0.39%)
AAPL   146.18 (-0.44%)
MSFT   298.02 (-0.51%)
FB   347.42 (+0.42%)
GOOGL   2,831.07 (+0.24%)
TSLA   764.28 (+1.41%)
AMZN   3,400.16 (-0.46%)
NVDA   219.24 (-2.48%)
BABA   145.80 (-3.57%)
NIO   35.51 (-1.39%)
CGC   13.99 (-3.91%)
GE   104.08 (+1.09%)
MU   74.38 (+0.46%)
AMD   105.00 (-1.08%)
T   27.29 (+0.37%)
F   13.93 (+1.60%)
ACB   6.01 (-2.28%)
DIS   175.56 (-0.39%)
PFE   44.18 (-0.02%)
BA   221.87 (+0.35%)
BAC   42.11 (+1.01%)
ASX:ANP

Antisense Therapeutics Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume1.32 million shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Receive ANP News and Ratings via Email

Sign-up to receive the latest news and ratings for Antisense Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


About Antisense Therapeutics

Antisense Therapeutics Limited, a biopharmaceutical company, engages in the research and development of novel antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor of CD49d that has completed Phase IIa for the treatment of multiple sclerosis, Duchennes Muscular Dystrophy, multiple sclerosis, asthma, and other inflammatory indications. The company's product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. Antisense Therapeutics Limited is based in Toorak, Australia.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

0.80 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Antisense Therapeutics (ASX:ANP) Frequently Asked Questions

What stocks does MarketBeat like better than Antisense Therapeutics?

Wall Street analysts have given Antisense Therapeutics a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Antisense Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Antisense Therapeutics' earnings last quarter?

Antisense Therapeutics Limited (ASX:ANP) posted its quarterly earnings data on Wednesday, February, 27th. The company reported $0.00 earnings per share for the quarter.
View Antisense Therapeutics' earnings history
.

Who are Antisense Therapeutics' key executives?

Antisense Therapeutics' management team includes the following people:
  • Mr. Mark Diamond B.Sc., M.B.A., BSc, MBA, MAICD, CEO, MD & Director
  • Mr. Phillip Allen Hains, CFO & Joint Company Sec. (Age 62, Pay $99k)
  • Ms. Alicia Mellors, Joint Company Sec.

What other stocks do shareholders of Antisense Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Antisense Therapeutics investors own include Tocagen (TOCA), Miragen Therapeutics (MGEN), Iovance Biotherapeutics (IOVA), Genocea Biosciences (GNCA), Capricor Therapeutics (CAPR) and Applied DNA Sciences (APDN).

What is Antisense Therapeutics' stock symbol?

Antisense Therapeutics trades on the ASX under the ticker symbol "ANP."

How much money does Antisense Therapeutics make?

Antisense Therapeutics has a market capitalization of $0.00 and generates $577,764.00 in revenue each year.

How many employees does Antisense Therapeutics have?

Antisense Therapeutics employs 8 workers across the globe.

What is Antisense Therapeutics' official website?

The official website for Antisense Therapeutics is www.antisense.com.au.

How can I contact Antisense Therapeutics?

The company can be reached via phone at 61 3 9827 8999.


This page was last updated on 9/24/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.